PE 22-28 (10 mg Vial) Dosage Protocol
PE 22-28 is a 7-amino-acid analog of spadin, studied as a fast-acting antidepressant via TREK-1 potassium channel inhibition.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (µg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 50 µg | 1.5 units (0.015 mL) |
| Weeks 3–4 | 100 µg | 3 units (0.03 mL) |
| Weeks 5–8 | 100 µg | 3 units (0.03 mL) |
| Weeks 9–12 (Optional) | 150 µg | 4.5 units (0.045 mL) |
| Weeks 13–16 (Optional) | 200 µg | 6 units (0.06 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses a practical 3.0 mL dilution for accurate measurement. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability. Many researchers find 100–150 µg sufficient given PE-22-28’s high potency.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration. Plan vial quantities from the dosing chart; follow product-specific use-by and sterile-handling instructions.
| Item | Quantity |
|---|---|
| Peptide Vials (PE-22-28, 10 mg each) | 8 weeks ≈ 2 vials 12 weeks ≈ 3 vials 16 weeks ≈ 4 vials |
| Insulin Syringes (U-100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (2 vials): 6 mL → 1 × 10 mL bottle 12 weeks (3 vials): 9 mL → 1 × 10 mL bottle 16 weeks (4 vials): 12 mL → 2 × 10 mL bottles |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100-count boxes 12 weeks: 168 swabs → recommend 2 × 100-count boxes 16 weeks: 224 swabs → recommend 3 × 100-count boxes |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 14 days, protect from light |
Important Notes
How This Works
PE 22-28 is a heptapeptide derived from spadin, the C-terminal fragment of sortilin. It selectively blocks the TREK-1 (KCNK2) potassium channel, which is highly expressed on serotonergic neurons. TREK-1 blockade enhances serotonergic neurotransmission and produces antidepressant effects in animal models — with onset much faster than SSRIs.
Potential Benefits & Side Effects
Potential Benefits
- Fast-acting antidepressant in rodent models (effects in days vs weeks).
- TREK-1 selective — distinct mechanism from SSRIs.
- No sedation or weight effects in available research.
Side Effect Profile
- Generally well-tolerated in animal research.
- Limited human clinical data.
Lifestyle Factors
- Pair with established mental-health practices (sleep, exercise, social connection).
- Animal data; not yet established in human trials.
Injection Technique
- Subcutaneous, rotate sites.